Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer

FIBROTHERME is a comparative, controlled, randomized, multicenter and simple blinded (investigator) trial. The aim of this study is to evaluate the medical benefit in terms of quality of life on the dermatological sequelae of fibrosis 6 months after a dermatologically oriented spa therapy in patients with severe late reactions affecting the skin and/or soft tissues at least 6 months after radiotherapy for breast cancer or UADT (Upper Aerodigestive Tract) cancer.

Trial Details

NCT ID
NCT05874492
Phase
NA
Sponsor
Association Francaise pour la Recherche Thermale
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Thermal cure with a primary dermatological indication
Locations (sample)
  • Bordeaux, France|44.84124,-0.58046
  • Créteil, France|48.79266,2.46569
  • Dijon, France|47.31344,5.01391
  • Grenoble, France|45.17869,5.71479
  • Grenoble, France|45.17869,5.71479

Key Eligibility Criteria

  • Age ≥ 18 years
  • In situ or invasive breast cancer or cancer of the upper aerodigestive tract
  • DLQI ≥ 6 (at least moderate effect on patient's life)
  • General status WHO 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →